Actinium Pharmaceuticals, Inc. ATNM
1.20
0.01
0.84%
as of 25 Sep
- Market cap
- $37.4M
- P/E
- 3.3×
Follow ATNM
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
P/S ratio |
235.70 | — | 137.41 | 234.86 | 108.06 | — | — | — | — | — |
P/FCF ratio |
0.00 | — | 0.00 | 29.22 | 0.00 | — | — | — | — | — |
P/Operating CF |
(8.02) | — | (18.90) | (31.10) | (24.47) | — | — | — | — | — |
P/B ratio |
5.42 | — | 3.89 | 3.64 | 1.68 | — | — | — | — | — |
Price to Tangible BV |
5.42 | — | 3.89 | 3.64 | 1.68 | — | — | — | — | — |
EV/Sales |
(28.04) | — | 63.49 | 131.24 | 39.91 | — | — | — | — | — |
EV/EBITDA |
0.14 | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
EV/Operating CF |
0.21 | — | (1.38) | 15.64 | (2.19) | — | — | — | — | — |
EV/FCF |
0.20 | — | (1.38) | 16.33 | (2.17) | — | — | — | — | — |
Quick Ratio |
6.02 | 8.95 | 9.03 | 10.28 | 11.44 | 13.34 | 1.74 | 2.26 | 3.73 | 4.55 |
Current Ratio |
6.20 | 9.14 | 9.21 | 10.44 | 11.66 | 13.62 | 1.89 | 2.36 | 3.82 | 4.95 |
Net Debt/EBITDA |
1.35 | 1.76 | 1.50 | 3.21 | 3.20 | 2.90 | 0.42 | 0.58 | 0.65 | 0.77 |
Debt/Assets |
0.00% | 0.01% | 0.02% | 1.82% | 0.00% | 0.10% | 1.29% | 0.09% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.73 | 0.86 | 0.97 | (0.26) | 0.84 | 0.97 | 0.98 | 0.87 | 0.81 | 0.85 |
Capex/Depreciation |
(0.13) | (0.01) | (0.19) | (0.52) | (0.25) | (0.57) | (0.15) | (1.90) | (0.44) | (0.77) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (166.96%) | (110.63%) | (94.92%) | (47.16%) | (36.74%) | (66.35%) | (302.99%) | (210.41%) | (167.94%) | (121.66%) | |
| (52.67%) | (48.30%) | (49.91%) | (33.94%) | (33.76%) | (56.92%) | (164.92%) | (142.38%) | (130.19%) | (99.04%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(81.25%) | (57.32%) | (69.42%) | (32.72%) | (33.82%) | (36.74%) | (450.92%) | (282.09%) | (201.06%) | (135.43%) |
Average Days of Receivables |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
23,471.11% | 0.00% | 47,740.74% | 2,246.12% | 1,576.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
16,903.33% | 0.00% | 16,458.02% | 1,164.95% | 706.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
10,211.11% | 0.00% | 4,743.21% | 271.36% | 148.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.13 | — | 0.23 | 0.26 | 0.59 | — | — | — | — | — |
Graham Number |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(79.41%) | — | (34.40%) | (13.57%) | (20.11%) | — | — | — | — | — |
Free Cash Flow Yield |
(58.18%) | — | (33.55%) | 3.42% | (16.99%) | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.04 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.79) | (1.10) | (1.78) | 0.36 | (1.01) | (1.78) | (4.31) | (5.83) | (9.70) | (12.88) |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.02) | (0.01) | (0.02) | (0.01) | (0.03) | (0.01) | (0.04) |
Free Cash Flow per Share |
(0.79) | (1.10) | (1.78) | 0.34 | (1.02) | (1.80) | (4.33) | (5.85) | (9.71) | (12.92) |
Cash per Share |
1.54 | 2.42 | 2.88 | 4.53 | 3.81 | 5.24 | 1.87 | 3.88 | 7.83 | 12.74 |
Shareholders Equity per Share |
0.25 | 1.09 | 1.37 | 2.75 | 3.58 | 5.05 | 1.13 | 2.50 | 6.15 | 11.16 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.25 | 1.09 | 1.37 | 2.75 | 3.58 | 5.05 | 1.13 | 2.50 | 6.15 | 11.16 |
Free Cash Flow |
(24.68) | (33.08) | (47.49) | 8.28 | (21.00) | (21.87) | (21.53) | (20.67) | (21.58) | (20.85) |
Working Capital |
41.41 | 66.36 | 69.77 | 100.31 | 72.91 | 60.16 | 4.74 | 8.27 | 13.17 | 17.87 |
Capital Expenditures |
(0.10) | (0.01) | (0.15) | (0.37) | (0.13) | (0.25) | (0.06) | (0.10) | (0.02) | (0.06) |
Net Current Asset Value |
5.44 | 30.37 | 33.20 | 63.23 | 72.91 | 59.85 | 4.06 | 8.25 | 13.17 | 17.87 |
EV/EBIT |
0.14 | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Capex to Sales |
1.16 | 0.00 | 1.89 | 0.36 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
(37,652.22%) | 0.00% | (60,269.14%) | (3,205.53%) | (2,165.56%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.78 | 2.23 | 1.44 | 1.16 | 1.54 | 1.43 | 3.72 | 0.43 | 0.97 | 0.88 |
Cash ROIC |
(44.55%) | (31.64%) | (42.35%) | 4.52% | (13.97%) | (17.54%) | (142.91%) | (91.79%) | (69.55%) | (54.14%) |
Accounts Receivable Turnover |
0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
7.41 | 7.76 | 9.04 | 7.83 | 4.94 | 4.47 | 5.21 | 5.23 | 4.44 | 2.86 |
Average Assets |
64.34 | 79.17 | 97.82 | 97.29 | 73.39 | 39.03 | 13.28 | 16.61 | 20.43 | 24.56 |
Average Common Equity |
20.30 | 34.57 | 51.43 | 70.01 | 67.43 | 33.48 | 7.23 | 11.24 | 15.84 | 19.99 |
Columns are period end dates